Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Capital Expenditures: 2016-2024

Historic Capital Expenditures for Organogenesis Holdings (ORGO) over the last 9 years, with Dec 2024 value amounting to $10.0 million.

  • Organogenesis Holdings' Capital Expenditures fell 13.00% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year increase of 28.66%. This contributed to the annual value of $10.0 million for FY2024, which is 58.82% down from last year.
  • Latest data reveals that Organogenesis Holdings reported Capital Expenditures of $10.0 million as of FY2024, which was down 58.82% from $24.4 million recorded in FY2023.
  • Over the past 5 years, Organogenesis Holdings' Capital Expenditures peaked at $33.9 million during FY2022, and registered a low of $10.0 million during FY2024.
  • Its 3-year average for Capital Expenditures is $22.8 million, with a median of $24.4 million in 2023.
  • Per our database at Business Quant, Organogenesis Holdings' Capital Expenditures spiked by 195.42% in 2020 and then tumbled by 58.82% in 2024.
  • Yearly analysis of 5 years shows Organogenesis Holdings' Capital Expenditures stood at $17.7 million in 2020, then skyrocketed by 76.60% to $31.2 million in 2021, then grew by 8.58% to $33.9 million in 2022, then fell by 28.13% to $24.4 million in 2023, then plummeted by 58.82% to $10.0 million in 2024.